<DOC>
	<DOCNO>NCT01910012</DOCNO>
	<brief_summary>Certain cancer require amino acid arginine . Arginine deiminase ( ADI ) enzyme microbe degrade arginine . ADI formulate polyethylene glycol use treat patient cancer require arginine . In study , investigator evaluate response rate , determine revise International Working Group recommendation .</brief_summary>
	<brief_title>PH 2 ADI-PEG 20 Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Acute myeloid leukemia ( AML ) diagnose morphologic , histochemical cell surface marker criterion . 2 . Patients AML must either : ( ) relapse refractory leukemia receive least one prior conventional induction therapy . Those early first relapse must match donor and/or must candidate allogeneic stem cell transplantation ( usually would mean patient ill , obese , comorbid condition age 55 year ) ( b ) poorrisk AML define : ( ) Treatment related AML , except associate favorable cytogenetics ( e.g. , inversion 16 , ( 16 ; 16 ) , ( 8 ; 21 ) , ( 15 ; 17 ) , candidate stem cell transplantation , ( ii ) AML antecedent hematologic disease ( e.g. , MDS , myelofibrosis , polycythemia vera , etc . ) , candidate stem cell transplantation . ( iii ) De novo AML &gt; 70 year age . ( iv ) AML unfavorable cytogenetics regardless age ( &gt; 18 year ) , patient candidate allogeneic transplantation . Unfavorable cytogenetics follow : complex ( &gt; 3 abnormality ) , 7 , 5 , 7q , 5q , abnormality 11q23 exclude ( 9 ; 11 ) , ( 9 ; 22 ) , inversion 3 , ( 3 ; 3 ) , ( 6 ; 9 ) . ( c ) Patients old 60 year age AML ( i.e. , &gt; 20 % bone marrow blast ) prior therapy AML 3 . Age ≥ 18 year . 4 . ECOG performance status 02 . 5 . Postmenarche female subject male subject must ask use appropriate contraception male female duration study . Subjects must agree use two form contraception agree refrain intercourse duration study . Females must pregnant start study , serum human chorionic gonadotropin ( HCG ) pregnancy test must negative entry study . 1 . Patients infection require intravenous ( IV ) antibiotic/antiviral therapy eligible entry onto study ; patient prophylactic antibiotic antiviral acceptable . 2 . Pregnancy lactation . 3 . Expected noncompliance . 4 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( New York Heart Association Class III IV ) , cardiac arrhythmia , psychiatric illness , social situation would limit compliance study requirement DIC . 5 . Subjects anticancer treatment prior enter study recover baseline ( except alopecia ) or≤ Grade 1 AEs , deem irreversible effect prior cancer therapy . AEs &gt; Grade 1 consider safety risk Sponsor investigator may allow upon agreement . 6 . Subjects history another primary cancer , include coexistent second malignancy , exception : ) curatively resect nonmelanoma skin cancer ; b ) curatively treated cervical carcinoma situ ; c ) primary solid tumor know active disease present opinion investigator affect patient outcome set current diagnosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Argininosuccinate Synthetase</keyword>
	<keyword>Arginine</keyword>
	<keyword>Arginine deiminase</keyword>
</DOC>